How to access Pomalyst from the UAE, the named-patient import pathway, 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-13.
An Emirati patient with relapsed or refractory multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor, or with Kaposi sarcoma after highly active antiretroviral therapy (HAART) failure or in HIV-negative patients, may receive a prescription for Pomalyst (pomalidomide) from their treating hematologist or oncologist. Pomalyst is FDA-approved in the United States and manufactured by Bristol Myers Squibb. It is an oral immunomodulatory drug (IMiD) administered by capsule. Local availability of Pomalyst in the UAE can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through MoHAP remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
Ask about Pomalyst in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Pomalyst is an oral immunomodulatory drug. Mechanism: a thalidomide analogue that binds cereblon, a substrate receptor of the CRL4 E3 ubiquitin ligase, with greater potency than lenalidomide and activity in some lenalidomide-refractory disease. Dosing: typically 4 mg orally once daily on days 1 through 21 of repeated 28-day cycles, per FDA labeling, in combination with dexamethasone for myeloma. Baseline workup per FDA labeling includes pregnancy testing in females of reproductive potential under the Pomalyst REMS program, CBC with differential, comprehensive metabolic panel, and venous thromboembolism risk review. Other important warnings include embryo-fetal toxicity (boxed warning), venous and arterial thromboembolism (boxed warning), hepatotoxicity, dizziness and confusional state, and second primary malignancies. Your hematologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Pomalyst legally importable into the UAE?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient and personal-use import framework, coordinated through an Emirati-licensed treating facility's pharmacy. The UAE has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The MoHAP named-patient route allows an Emirati-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.
How the pathway works, step by step
- Consultation with your treating hematologist. The prescribing decision is clinical. Your hematologist documents the indication, prior lenalidomide and PI exposure for myeloma, and rationale for Pomalyst.
- Baseline screening. Pregnancy testing under REMS-equivalent process for females of reproductive potential, CBC with differential, comprehensive metabolic panel, and VTE risk review are confirmed and documented.
- MoHAP named-patient application. Your hematologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from Bristol Myers Squibb's authorised distribution under DSCSA chain-of-custody.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your hematologist initiates therapy.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis (r/r MM post lenalidomide and PI, or Kaposi sarcoma per labeled setting), prior therapies, and Pomalyst as the indicated next step
- Verification of their UAE medical licence
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening consistent with FDA labeling (see above), including pregnancy testing where applicable
- The planned dosing regimen (4 mg orally on days 1 through 21 of 28-day cycles, with dexamethasone for myeloma, per FDA labeling)
- A monitoring plan covering CBC at regular intervals, pregnancy surveillance for females of reproductive potential, and VTE prophylaxis plan
Reserve Meds provides a physician documentation kit tailored for IMiD therapies, including the templates MoHAP reviewers commonly request.
Typical costs and indicative timing
Reserve Meds gives you a transparent, itemised custom quote at intake. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, MoHAP documentation handling, and coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling cadence aligned to the cycle schedule.
Where Reserve Meds fits in
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Pomalyst specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for MoHAP review, including IMiD class templates.
- Logistics. Internationally tracked shipment to your named dispensing facility with tamper-evident packaging.
- Dedicated case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating hematologist, and dispensing sits with the licensed UAE pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at the UAE tertiary centers.
Will my private health insurance cover this? Cash-pay is the default posture. Some UAE private insurers (Daman, AXA, Mednet-administered plans) reimburse named-patient imports on a case-by-case basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.
How does Pomalyst differ from Revlimid? Both are oral cereblon-binding IMiDs. Pomalidomide is more potent and retains activity in some lenalidomide-refractory myeloma, which is why FDA labeling positions Pomalyst after lenalidomide and a proteasome inhibitor have already been tried. The choice between continuing IMiD therapy and switching class is a clinical decision your hematologist will make.
What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major UAE tertiary centers (Cleveland Clinic Abu Dhabi, Tawam Hospital Al Ain, American Hospital Dubai, and Mediclinic City Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what MoHAP reviewers commonly ask for.
Next step
For Pomalyst coordination in the UAE, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Pomalyst in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Pomalyst for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Pomalyst in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Pomalyst. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Pomalyst in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Pomalyst to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Pomalyst to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Pomalyst in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Pomalyst in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.